Astellas Pharma Q1 revenue up 6.9%, profit soars 61%

Astellas Pharma reported Q1 FY2025 revenue rose 6.9% to 505.8bn yen, with core operating profit surging 61.1% to 142.3bn yen.

Growth was driven by strong sales of PADCEV (up 44.6%), IZERVAY (up 25.2%), VEOZAH (up 45.6%), and newly launched VYLOY contributing 14bn yen. China revenue jumped 57.8%.

R&D expenses fell 17.4% to 71.7bn yen due to foreign exchange impact and cost optimization. The company maintained its full-year forecast of 1.93 trillion yen revenue and 160bn yen core operating profit.